Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 2/2008

01-02-2008 | Original Paper

HLA DRB1*13 as a Risk Factor for Type 1 Autoimmune Hepatitis in North American Patients

Authors: Albert J. Czaja, Herschel A. Carpenter, S. Breanndan Moore

Published in: Digestive Diseases and Sciences | Issue 2/2008

Login to get access

Abstract

Our goal was to determine if HLA DRB1*13 is associated with autoimmune hepatitis in North American patients. Two hundred and ten adults with definite type 1 autoimmune hepatitis were typed by DNA-based techniques, and the frequency of HLA DRB1*13 in patients without DRB1*03 and DRB1*04 was compared to that in 396 patients with eight other chronic liver diseases and 102 normal individuals. HLA DRB1*13 occurred more commonly in the autoimmune patients who lacked DRB1*03 and DRB1*04 than normal subjects who were similarly restricted (56% vs. 27%, P = 0.007). The frequency of HLA DRB1*13 was higher in autoimmune patients without DRB1*03 and DRB1*04 than in patients with other chronic liver diseases who were similarly restricted (59% vs. 32%, P = 0.01). Only patients with primary sclerosing cholangitis had a comparable occurrence of HLA DRB1*13. In conclusion, HLA DRB1*13 may be a genetic risk factor for some white North American patients with type 1 autoimmune hepatitis.
Literature
1.
Fainboim L, Marcos Y, Pando M, Capucchio M, Reyes GB, Galoppo C, Badia I, Remondino G, Ciocca M, Ramonet M, Fainboim H, Satz ML (1994) Chronic active autoimmune hepatitis in children. Strong association with a particular HLA DR6 (DRB1*1301) haplotype. Hum Immunol 41:146–150PubMedCrossRef
2.
Pando M, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M, Badia I, Daruich J, Findor J, Tanno H, Canero-Velasco C, Fainboim L (1999) Pediatric and adult forms of type 1 autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 30:1374–1380PubMedCrossRef
3.
Bittencourt PL, Goldberg AC, Cancado ELR, Porta G, Carrilho FJ, Farias AQ, Palacios SA, Chiarella JM, Abrantes-Lemos CP, Baggio VL, Laudanna AA, Kalil J (1999) Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 94:1906–1913PubMedCrossRef
4.
Goldberg AC, Bittencourt PL, Mougin B, Cancado ELR, Porta G, Carrilho F, Kalil J (2001) Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum Immunol 62:165–169PubMedCrossRef
5.
Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R (1991) Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 13:701–706PubMed
6.
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB (1993) Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 105:1502–1507PubMed
7.
Doherty DG, Donaldson PT, Underhill JA, Farrant JM, Duthie A, Mieli-Vergani G, McFarlane IG, Johnson PJ, Eddleston ALWF, Mowat AP, Williams R (1994) Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 19:609–615PubMedCrossRef
8.
Fainboim L, Velasco VCC, Marcos CY, Ciocca M, Roy A, Theiler G, Capucchio M, Nuncifora S, Sala L, Zelazko M (2001) Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB1*1301, a marker for pediatric autoimmune hepatitis. Hepatology 33:1512–1517PubMedCrossRef
9.
Lango-Warensjo A, Cardell K, Lindblom B (1998) Haplotypes comprising subtypes of the HLA-DQB1*06 allele direct the antibody response after immunization with hepatitis B surface antigen. Tissue Antigens 52:374–380PubMed
10.
Czaja AJ, Souto EO, Bittencourt PL, Cancado ELR, Porto G, Goldberg AC, Donaldson PT (2002) Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 37:302–308PubMedCrossRef
11.
Czaja AJ, Carpenter HA, Moore SB (2006) Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4. Liver Int 26:552–558PubMedCrossRef
12.
Czaja AJ, Freese DK (2002) Diagnosis and treatment of autoimmune hepatitis. Hepatology 36:479–497PubMedCrossRef
13.
Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WGE, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston ALWF, Fainboim L, Heathcote J, Homberg J-C, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RNM, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Buschenfelde K-H, Mieli-Vergani G, Nakanuma Y, Nishioka M, Penner E, Porta G, Portmann BC, Reed WD, Rodes J, Schalm SW, Scheuer PJ, Schrumpf E, Seki T, Toda G, Tsuji T, Tygstrup N, Vergani D, Zeniya M (1999) International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929–938PubMedCrossRef
14.
15.
Czaja AJ (2005) Current concepts in autoimmune hepatitis. Ann Hepatol 4:6–24PubMed
16.
Czaja AJ, Carpenter HA (1993) Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105:1824–1832PubMed
17.
Czaja AJ, Santrach PJ, Moore SB (2001) Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci 46:140–147PubMedCrossRef
18.
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB (1996) Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J Hepatol 24:52–59PubMedCrossRef
19.
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA (1993) The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 104:1755–1761PubMed
20.
Czaja AJ, Donaldson PT (2000) Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 174:250–259PubMedCrossRef
21.
Czaja AJ, Doherty DG, Donaldson PT (2002) Genetic bases of autoimmune hepatitis. Dig Dis Sci 47:2139–2150PubMedCrossRef
22.
Donaldson PT, Czaja AJ (2002) Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin Liver Dis 6:707–725PubMedCrossRef
23.
24.
Doherty DG, Penzotti JE, Koelle DM, Kwok WW, Lybrand TP, Masewicz S, Nepom GT (1998) Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol 161:3527–3535PubMed
25.
Singal DP, Li J, Zhu Y (1999) Genetic basis for rheumatoid arthritis. Arch Immunol Ther Exp 47:307–311
26.
Tapia-Conyer R, Santos JI, Cavalcanti AM, Urdaneta E, Rivera L, Manterola A, Potin M, Ruttiman R, Tanaka-Kido J (1999) Hepatitis A in Latin America: a changing epidemiologic pattern. Am J Trop Med Hyg 61:825–829PubMed
27.
Vento S, Garofano T, Di Perri G, Dolci L, Concia E, Bassetti D (1991) Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 337:1183–1187PubMedCrossRef
28.
Huppertz H-K, Treichel U, Gassel AM, Jeschke R, Meyer zum Buschenfelde K-H (1995) Autoimmune hepatitis following hepatitis A virus infection. J Hepatol 23:204–208PubMedCrossRef
29.
Tanaka H, Tujioka H, Ueda H, Hamagami H, Kida Y, Ichinose M (2005) Autoimmune hepatitis triggered by acute hepatitis A. World J Gastroenterol 11:6069–6071PubMed
30.
Schreuder GM, Hurley CK, Marsh SG, Lau M, Maiers M, Kollman C, Noreen HJ (2001) The HLA dictionary 2001: a summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and –DQ antigens. Hum Immunol 62:826–849PubMedCrossRef
31.
Hill A, Allsopp C, Kwiatkowski D, Anstey N, Twumasi P, Rowe P, Bennet S, Brewster D, McMichael AJ, Greenwood BM (1991) Common West African HLA antigens are associated with protection from severe malaria. Nature 352:595–600PubMedCrossRef
32.
Farrant JM, Doherty DG, Donaldson PT, Vaughan RW, Hayllar KM, Welsh KI, Eddleston ALWF, Williams R (1992) Amino acid substitutions at position 38 of the DRβ polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology 16:390–395PubMedCrossRef
33.
Boberg KM, Spurkland A, Rocca G, Egeland T, Saarinen S, Mitchell S, Broome U, Chapman R, Olerup O, Pares A, Rosina F, Schrumpf E (2001) The HLA-DR3, Dq2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scand J Gastroenterol 36:886–890PubMedCrossRef
34.
Donaldson PT, Norris S (2001) Immunogenetics in PSC. Best Practice Res Clin Gastroenterol 15:611–627CrossRef
35.
Donaldson PT, Norris S (2002) Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 35:555–564PubMedCrossRef
Metadata
Title
HLA DRB1*13 as a Risk Factor for Type 1 Autoimmune Hepatitis in North American Patients
Authors
Albert J. Czaja
Herschel A. Carpenter
S. Breanndan Moore
Publication date
01-02-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-9859-4

Other articles of this Issue 2/2008

Digestive Diseases and Sciences 2/2008 Go to the issue

Original Paper

Visceral and Somatic Hypersensitivity in TNBS-Induced Colitis in Rats

Original Paper

Association between Proton Pump Inhibitor Use and Spontaneous Bacterial Peritonitis

Original Paper

Omeprazole Inhibits Natural Killer Cell Functions

Original Paper

Prevalence of Macrocreatinkinase Type 1 in Patients with Inflammatory Bowel Disease

Original Paper

The Activity of RhoA is Correlated with Lymph Node Metastasis in Human Colorectal Cancer

Original Paper

Novel Biodegradable Stents for Benign Esophageal Strictures Following Endoscopic Submucosal Dissection
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits